Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. American heart journal Cohen, A. T., Harrington, R., Goldhaber, S. Z., Hull, R., Gibson, C. M., Hernandez, A. F., Gold, A. 2015; 169 (1): 186-187
View details for DOI 10.1016/j.ahj.2014.09.004
View details for PubMedID 25497265